For: | Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008; 14(36): 5584-5589 [PMID: 18810778 DOI: 10.3748/wjg.14.5584] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v14/i36/5584.htm |
Number | Citing Articles |
1 |
Peng Fei, Junliang Chen, Yichao Jiang, Hongjian Bai, Yanyan Wang, Ying Han, Min Xing, Ling Guo. Rotavirus-Induced Diarrhea Changes the Proteins, Amino Acids and Fatty Acids Profiles in Fecal Samples of the Infants. Iranian Journal of Pediatrics 2021; 31(1) doi: 10.5812/ijp.100031
|
2 |
Ibrahim Masoodi, Rakesh Kochhar, Usha Dutta, Chetana Vaishnavi, K. K. Prasad, Kim Vaiphei, Shabnum Hussain, Kartar Singh. Evaluation of Fecal Myeloperoxidase as a Biomarker of Disease Activity and Severity in Ulcerative Colitis. Digestive Diseases and Sciences 2012; 57(5): 1336 doi: 10.1007/s10620-012-2027-5
|
3 |
Mohsen Hanifeh, Romy M. Heilmann, Satu Sankari, Minna M. Rajamäki, Laura Mäkitalo, Pernilla Syrjä, Susanne Kilpinen, Jan S. Suchodolski, Jörg M. Steiner, Thomas Spillmann. S100A12 concentrations and myeloperoxidase activity in the intestinal mucosa of healthy dogs. BMC Veterinary Research 2015; 11(1) doi: 10.1186/s12917-015-0551-1
|
4 |
Ren Mao, Ying-lian Xiao, Xiang Gao, Bai-li Chen, Yao He, Li Yang, Pin-jin Hu, Min-hu Chen. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies. Inflammatory Bowel Diseases 2012; 18(10): 1894 doi: 10.1002/ibd.22861
|
5 |
M. Koláček, J. Muchová, M. Dvořáková, Z. Paduchová, I. Žitňanová, I. Čierna, Z. Országhová, D. Székyová, N. Jajcaiová-Zedníčková, L. Kovács, Z. Ďuračková. Effect of natural polyphenols (Pycnogenol) on oxidative stress markers in children suffering from Crohn's disease – a pilot study. Free Radical Research 2013; 47(8): 624 doi: 10.3109/10715762.2013.807508
|
6 |
Maria Gloria Mumolo, Lorenzo Bertani, Linda Ceccarelli, Gabriella Laino, Giorgia Di Fluri, Eleonora Albano, Gherardo Tapete, Francesco Costa. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. World Journal of Gastroenterology 2018; 24(33): 3681-3694 doi: 10.3748/wjg.v24.i33.3681
|
7 |
Mirko Di Ruscio, Filippo Vernia, Antonio Ciccone, Giuseppe Frieri, Giovanni Latella. Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin?. Inflammatory Bowel Diseases 2018; 24(1): 78 doi: 10.1093/ibd/izx011
|
8 |
Aart Mookhoek, Maria L Haasnoot, Albert J Bredenoord, Christopher Ma, Vipul Jairath, Rish K Pai. The Clinical Significance of Eosinophils in Ulcerative Colitis: A Systematic Review. Journal of Crohn's and Colitis 2022; 16(8): 1321 doi: 10.1093/ecco-jcc/jjac024
|
9 |
Shingo HINO, Hiroyuki ITO, Hiroyuki BITO, Hirokazu KAWAGISHI, Tatsuya MORITA. Ameliorating Effects of Short-Chain Inulin-Like Fructans on the Healing Stage of Trinitrobenzene Sulfonic Acid-Induced Colitis in Rats. Bioscience, Biotechnology, and Biochemistry 2011; 75(11): 2169 doi: 10.1271/bbb.110460
|
10 |
Maureen C. Turina, Robert Landewé, Dominique Baeten. Lessons to be learned from serum biomarkers in psoriasis and IBD – the potential role in SpA. Expert Review of Clinical Immunology 2017; 13(4): 333 doi: 10.1080/1744666X.2017.1244004
|
11 |
Natalia Pedersen, Pia Munkholm. Reply to Methodological Approach to Mesalazine Treatment in Patients with Mild-to-moderate Ulcerative Colitis. Inflammatory Bowel Diseases 2015; 21(8): E15 doi: 10.1097/MIB.0000000000000484
|
12 |
Jose-Manuel Benitez, Marie-Alice Meuwis, Catherine Reenaers, Catherine Van Kemseke, Paul Meunier, Edouard Louis. Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring. Gut 2013; 62(12): 1806 doi: 10.1136/gutjnl-2012-303957
|
13 |
Taina Sipponen. Diagnostics and Prognostics of Inflammatory Bowel Disease with Fecal Neutrophil-Derived Biomarkers Calprotectin and Lactoferrin. Digestive Diseases 2013; 31(3-4): 336 doi: 10.1159/000354689
|
14 |
Devis Benfaremo, Michele Maria Luchetti, Armando Gabrielli. Biomarkers in Inflammatory Bowel Disease-Associated Spondyloarthritis: State of the Art and Unmet Needs. Journal of Immunology Research 2019; 2019: 1 doi: 10.1155/2019/8630871
|
15 |
James D. Falvey, Teagan Hoskin, Berrie Meijer, Anna Ashcroft, Russell Walmsley, Andrew S. Day, Richard B. Gearry. Disease Activity Assessment in IBD. Inflammatory Bowel Diseases 2015; 21(4): 824 doi: 10.1097/MIB.0000000000000341
|
16 |
Michael Wagner, Klas Sjöberg, Lina Vigren, Martin Olesen, Cecilia Benoni, Ervin Toth, Marie Carlson. Elevated fecal levels of eosinophil granule proteins predict collagenous colitis in patients referred to colonoscopy due to chronic non-bloody diarrhea. Scandinavian Journal of Gastroenterology 2016; 51(7): 835 doi: 10.3109/00365521.2016.1141432
|
17 |
Jordi Guardiola, Triana Lobatón, Elena Cerrillo, Rocío Ferreiro-Iglesias, Javier P. Gisbert, Eugeni Domènech, María Chaparro, Maria Esteve, Francisco Rodríguez-Moranta. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. Gastroenterología y Hepatología (English Edition) 2018; 41(8): 514 doi: 10.1016/j.gastre.2018.05.018
|
18 |
Michael Wagner, Mats Stridsberg, Christer G. B. Peterson, Per Sangfelt, Maria Lampinen, Marie Carlson. Increased Fecal Levels of Chromogranin A, Chromogranin B, and Secretoneurin in Collagenous Colitis. Inflammation 2013; 36(4): 855 doi: 10.1007/s10753-013-9612-4
|
19 |
Marisa Iborra, Belén Beltrán, Pilar Nos. Noninvasive Testing for Mucosal Inflammation in Inflammatory Bowel Disease. Gastrointestinal Endoscopy Clinics of North America 2016; 26(4): 641 doi: 10.1016/j.giec.2016.06.005
|
20 |
Teagan S. Edwards, Andrew S. Day. The role of fecal biomarkers in individuals with inflammatory bowel disease. Expert Review of Molecular Diagnostics 2024; 24(6): 497 doi: 10.1080/14737159.2024.2375224
|
21 |
James Turvill. Mapping of Crohn's disease outcomes to faecal calprotectin levels in patients maintained on biologic therapy. Frontline Gastroenterology 2014; 5(3): 167 doi: 10.1136/flgastro-2014-100441
|
22 |
Akhilesh Swaminathan, Grace M Borichevsky, Teagan S Edwards, Esther Hirschfeld, Thomas C Mules, Chris M A Frampton, Andrew S Day, Mark B Hampton, Anthony J Kettle, Richard B Gearry. Faecal Myeloperoxidase as a Biomarker of Endoscopic Activity in Inflammatory Bowel Disease. Journal of Crohn's and Colitis 2022; 16(12): 1862 doi: 10.1093/ecco-jcc/jjac098
|
23 |
V. Kristensen, P. Klepp, M. Cvancarova, A. Roseth, V. Skar, B. Moum. Prediction of Endoscopic Disease Activity in Ulcerative Colitis by Two Different Assays for Fecal Calprotectin. Journal of Crohn's and Colitis 2015; 9(2): 164 doi: 10.1093/ecco-jcc/jju015
|
24 |
Veljko Maric, Milan Jovanovic, Natasa Zdravkovic, Marina Jovanovic, Nevena Gajovic, Milena Jurisevic, Marina Jovanovic, Ivan Jovanovic. Increased IL-33 and IL-17 in Colorectal Carcinoma Patients with Severe Disease. Serbian Journal of Experimental and Clinical Research 2020; 21(3): 239 doi: 10.2478/sjecr-2018-0034
|
25 |
Philipp Lenz, Dominik Bettenworth, Philipp Krausewitz, Markus Brückner, Steffi Ketelhut, Gert von Bally, Dirk Domagk, Björn Kemper. Digital holographic microscopy quantifies the degree of inflammation in experimental colitis. Integrative Biology 2013; 5(3): 624 doi: 10.1039/c2ib20227a
|
26 |
James Turvill, Lisa Rook, Maxine Rawle, Gerry Robins, Simon Smale, Prashant Kant, Anne Phillips. Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease. Frontline Gastroenterology 2017; 8(3): 183 doi: 10.1136/flgastro-2016-100780
|
27 |
Belal Chami, Patrick T. San Gabriel, Stephen Kum-Jew, XiaoSuo Wang, Nina Dickerhof, Joanne M. Dennis, Paul K. Witting. The nitroxide 4-methoxy-tempo inhibits the pathogenesis of dextran sodium sulfate-stimulated experimental colitis. Redox Biology 2020; 28: 101333 doi: 10.1016/j.redox.2019.101333
|
28 |
Karin Leder, John J Openshaw, Pascale Allotey, Ansariadi Ansariadi, S Fiona Barker, Kerrie Burge, Thomas F Clasen, Steven L Chown, Grant A Duffy, Peter A Faber, Genie Fleming, Andrew B Forbes, Matthew French, Chris Greening, Rebekah Henry, Ellen Higginson, David W Johnston, Rachael Lappan, Audrie Lin, Stephen P Luby, David McCarthy, Joanne E O'Toole, Diego Ramirez-Lovering, Daniel D Reidpath, Julie A Simpson, Sheela S Sinharoy, Rohan Sweeney, Ruzka R Taruc, Autiko Tela, Amelia R Turagabeci, Jane Wardani, Tony Wong, Rebekah Brown. Study design, rationale and methods of the Revitalising Informal Settlements and their Environments (RISE) study: a cluster randomised controlled trial to evaluate environmental and human health impacts of a water-sensitive intervention in informal settlements in Indonesia and Fiji. BMJ Open 2021; 11(1): e042850 doi: 10.1136/bmjopen-2020-042850
|
29 |
Xiaorong Su, Zhen-hua Zhu, Lin Zhang, Qian Wang, Ming-ming Xu, Cai Lu, Yue Zhu, Jianguo Zeng, Jin-Ao Duan, Ming Zhao. Anti-inflammatory property and functional substances of Lonicerae Japonicae Caulis. Journal of Ethnopharmacology 2021; 267: 113502 doi: 10.1016/j.jep.2020.113502
|
30 |
Anders Lasson, Lena Öhman, Per-Ove Stotzer, Stefan Isaksson, Otto Überbacher, Kjell-Arne Ung, Hans Strid. Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study. United European Gastroenterology Journal 2015; 3(1): 72 doi: 10.1177/2050640614560785
|
31 |
Gary R Lichtenstein, Dermot P B McGovern. Using Markers in IBD to Predict Disease and Treatment Outcomes: Rationale and a Review of Current Status. The American Journal of Gastroenterology Supplements 2016; 3(3): 17 doi: 10.1038/ajgs.2016.17
|
32 |
Abdelrahim Alqudah, Esam Qnais, Omar Gammoh, Yousra Bseiso, Mohammed Wedyan, Mohammad Alqudah, Taher Hatahet. Cirsimaritin Alleviates Dextran Sodium Sulfate-Induced Acute Colitis in Experimental Animals: A Therapeutic Approach for Inflammatory Bowel Disease. Preventive Nutrition and Food Science 2024; 29(1): 31 doi: 10.3746/pnf.2024.29.1.31
|
33 |
Michael Wagner, Christer G. B. Peterson, Ingrid Stolt, Per Sangfelt, Margret Agnarsdottir, Maria Lampinen, Marie Carlson. Fecal eosinophil cationic protein as a marker of active disease and treatment outcome in collagenous colitis: A pilot study. Scandinavian Journal of Gastroenterology 2011; 46(7-8): 849 doi: 10.3109/00365521.2011.571707
|
34 |
Jordi Guardiola, Triana Lobatón, Elena Cerrillo, Rocío Ferreiro-Iglesias, Javier P. Gisbert, Eugeni Domènech, María Chaparro, Maria Esteve, Francisco Rodríguez-Moranta. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la utilidad de la determinación de calprotectina fecal en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2018; 41(8): 514 doi: 10.1016/j.gastrohep.2018.05.029
|
35 |
Lorenzo Bertani, Maria Gloria Mumolo, Gherardo Tapete, Eleonora Albano, Giovanni Baiano Svizzero, Federico Zanzi, Linda Ceccarelli, Massimo Bellini, Santino Marchi, Francesco Costa. Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment. European Journal of Gastroenterology & Hepatology 2020; 32(9): 1091 doi: 10.1097/MEG.0000000000001731
|
36 |
Shapur Ikhtaire, Mohammad Sharif Shajib, Walter Reinisch, Waliul Islam Khan. Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease. Journal of Gastroenterology 2016; 51(5): 434 doi: 10.1007/s00535-016-1182-4
|
37 |
Xu Zhang, Shelley A. Deeke, Zhibin Ning, Amanda E. Starr, James Butcher, Jennifer Li, Janice Mayne, Kai Cheng, Bo Liao, Leyuan Li, Ruth Singleton, David Mack, Alain Stintzi, Daniel Figeys. Metaproteomics reveals associations between microbiome and intestinal extracellular vesicle proteins in pediatric inflammatory bowel disease. Nature Communications 2018; 9(1) doi: 10.1038/s41467-018-05357-4
|
38 |
Sachin Kadian, Sarath Gopalakrishnan, Vidhya Selvamani, Sadid Khan, Trevor Meyer, Rithu Thomas, Muhammad Masud Rana, Pedro P. Irazoqui, Mohit S. Verma, Rahim Rahimi. Smart Capsule for Targeted Detection of Inflammation Levels Inside the GI Tract. IEEE Transactions on Biomedical Engineering 2024; 71(5): 1565 doi: 10.1109/TBME.2023.3343337
|
39 |
Anne-Claire Frin, Jérôme Filippi, Gilles Boschetti, Bernard Flourie, Jocelyne Drai, Patricia Ferrari, Xavier Hebuterne, Stéphane Nancey. Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis. Digestive and Liver Disease 2017; 49(1): 11 doi: 10.1016/j.dld.2016.09.001
|
40 |
J.K. Yamamoto-Furusho, F. Bosques-Padilla, J. de-Paula, M.T. Galiano, P. Ibañez, F. Juliao, P.G. Kotze, J.L. Rocha, F. Steinwurz, G. Veitia, C. Zaltman. Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México (English Edition) 2017; 82(1): 46 doi: 10.1016/j.rgmxen.2016.07.003
|
41 |
Nour Eissa, Hayam Hussein, Diane M. Tshikudi, Geoffrey N. Hendy, Charles N. Bernstein, Jean-Eric Ghia. Interdependence between Chromogranin-A, Alternatively Activated Macrophages, Tight Junction Proteins and the Epithelial Functions. A Human and In-Vivo/In-Vitro Descriptive Study. International Journal of Molecular Sciences 2020; 21(21): 7976 doi: 10.3390/ijms21217976
|
42 |
Jason Orlando Dimitri Musci, Jack Stephen Cornish, Jan Däbritz. Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases. Journal of Gastroenterology 2016; 51(6): 531 doi: 10.1007/s00535-016-1191-3
|
43 |
J.K. Yamamoto-Furusho, F. Bosques-Padilla, J. de-Paula, M.T. Galiano, P. Ibañez, F. Juliao, P.G. Kotze, J.L. Rocha, F. Steinwurz, G. Veitia, C. Zaltman. Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México 2017; 82(1): 46 doi: 10.1016/j.rgmx.2016.07.003
|
44 |
Ignazio Brusca. Biomarcatori nelle malattie infiammatorie intestinali. La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine 2013; 9(3): 123 doi: 10.1007/s13631-013-0012-4
|
45 |
Anneline Cremer, Jade Ku, Leila Amininejad, Marie-Rose Bouvry, Fabian Brohet, Claire Liefferinckx, Jacques Devière, André van Gossum, Julie Smet, Patrick Stordeur, Denis Franchimont. Variability of Faecal Calprotectin in Inflammatory Bowel Disease Patients: An Observational Case-control Study. Journal of Crohn's and Colitis 2019; 13(11): 1372 doi: 10.1093/ecco-jcc/jjz069
|
46 |
Mariann Rutka, Renáta Bor, Anita Bálint, Anna Fábián, Ágnes Milassin, Ferenc Nagy, Zoltán Szepes, Mónika Szűcs, László Tiszlavicz, Klaudia Farkas, Tamás Molnár. Diagnostic Accuracy of Five Different Fecal Markers for the Detection of Precancerous and Cancerous Lesions of the Colorectum. Mediators of Inflammation 2016; 2016: 1 doi: 10.1155/2016/2492081
|
47 |
Shiyang Li, Ning Yuan, Wei Guo, Yuan Chai, Yi Song, Yuanhui Zhao, Mingyong Zeng, Haohao Wu. Antioxidant and anti-inflammatory protective effects of yellowtail (Seriola quinqueradiata) milt hydrolysates on human intestinal epithelial cells in vitro and dextran sodium sulphate-induced mouse colitis in vivo. Food & Function 2022; 13(18): 9169 doi: 10.1039/D2FO00967F
|
48 |
Belal Chami, Nathan J.J. Martin, Joanne M. Dennis, Paul K. Witting. Myeloperoxidase in the inflamed colon: A novel target for treating inflammatory bowel disease. Archives of Biochemistry and Biophysics 2018; 645: 61 doi: 10.1016/j.abb.2018.03.012
|
49 |
Maria E. Moscandrew, Edward V. Loftus. Diagnostic advances in inflammatory bowel disease (imaging and laboratory). Current Gastroenterology Reports 2009; 11(6): 488 doi: 10.1007/s11894-009-0074-7
|
50 |
Francisco Rodríguez-Moranta, Triana Lobatón, Lorena Rodríguez-Alonso, Jordi Guardiola. Calprotectina fecal en el diagnóstico de enfermedades inflamatorias. Gastroenterología y Hepatología 2013; 36(6): 400 doi: 10.1016/j.gastrohep.2012.10.008
|
51 |
Inbar Weinstein-Nakar, Gili Focht, Peter Church, Thomas D. Walters, Guila Abitbol, Sudha Anupindi, Laureline Berteloot, Jessie M. Hulst, Frank Ruemmele, Daniel A. Lemberg, Steven T. Leach, Ruth Cytter, Mary-Louise Greer, Anne M. Griffiths, Dan Turner. Associations Among Mucosal and Transmural Healing and Fecal Level of Calprotectin in Children With Crohn’s Disease. Clinical Gastroenterology and Hepatology 2018; 16(7): 1089 doi: 10.1016/j.cgh.2018.01.024
|
52 |
Maria Elena Rodríguez-Cabezas, Desirée Camuesco, Belén Arribas, Natividad Garrido-Mesa, Mònica Comalada, Elvira Bailón, Margarita Cueto-Sola, Pilar Utrilla, Eduardo Guerra-Hernández, Carlos Pérez-Roca, Julio Gálvez, Antonio Zarzuelo. The combination of fructooligosaccharides and resistant starch shows prebiotic additive effects in rats. Clinical Nutrition 2010; 29(6): 832 doi: 10.1016/j.clnu.2010.05.005
|
53 |
Laura Mäkitalo, Hanne Rintamäki, Taina Tervahartiala, Timo Sorsa, Kaija-Leena Kolho. Serum MMPs 7–9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2012; 47(7): 785 doi: 10.3109/00365521.2012.677954
|
54 |
Fabrizia D'Angelo, Christian Felley, Jean Louis Frossard. Calprotectin in Daily Practice: Where Do We Stand in 2017?. Digestion 2017; 95(4): 293 doi: 10.1159/000476062
|
55 |
Graham D. Naismith, Lyn A. Smith, Sarah J.E. Barry, Joanna I. Munro, Susan Laird, Karen Rankin, Allan J. Morris, Jack W. Winter, Daniel R. Gaya. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease. Journal of Crohn's and Colitis 2014; 8(9): 1022 doi: 10.1016/j.crohns.2014.01.029
|
56 |
William C. Reisdorf, Qing Xie, Xin Zeng, Wensheng Xie, Neetu Rajpal, Bao Hoang, Mark E. Burgert, Vinod Kumar, Mark R. Hurle, Deepak K. Rajpal, Sarah O’Donnell, Thomas T. MacDonald, Anna Vossenkämper, Lin Wang, Mike Reilly, Bart J. Votta, Yolanda Sanchez, Pankaj Agarwal, Fulvio D'Acquisto. Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease. PLOS ONE 2019; 14(4): e0215033 doi: 10.1371/journal.pone.0215033
|
57 |
Fang Chen, Yue Hu, Yi-Hong Fan, Bin Lv. Clinical Value of Fecal Calprotectin in Predicting Mucosal Healing in Patients With Ulcerative Colitis. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.679264
|
58 |
G. D. Naismith, L. A. Smith, S. J. E. Barry, J. I. Munro, S. Laird, K. Rankin, A. J. Morris, J. W. Winter, D. R. Gaya. A prospective single‐centre evaluation of the intra‐individual variability of faecal calprotectin in quiescent Crohn's disease. Alimentary Pharmacology & Therapeutics 2013; 37(6): 613 doi: 10.1111/apt.12221
|
59 |
Ahmed Kouki, Wafa Ferjani, Pham My-Chan Dang, Néziha Ghanem-Boughanmi, Abdelaziz Souli, Mossadok Ben-Attia, Jamel El-Benna. Preventive Anti-inflammatory Effects of Apocynin on Acetic Acid–Induced Colitis in Rats. Inflammation 2024; 47(1): 438 doi: 10.1007/s10753-023-01920-4
|
60 |
Vendel Kristensen, Trine Lauritzen, Lars-Petter Jelsness-Jørgensen, Svein Oskar Frigstad, Christian Corwin, Bjørn Moum. Patient-performed extraction of faecal calprotectin. Clinical Chemistry and Laboratory Medicine (CCLM) 2016; 54(8) doi: 10.1515/cclm-2015-1037
|
61 |
Karin Amcoff, Yang Cao, Yaroslava Zhulina, Maria Lampinen, Jonas Halfvarson, Marie Carlson. Prognostic significance of faecal eosinophil granule proteins in inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2019; 54(10): 1237 doi: 10.1080/00365521.2019.1670251
|
62 |
Floor van de Logt, Andrew S Day. S100A12: A noninvasive marker of inflammation in inflammatory bowel disease. Journal of Digestive Diseases 2013; 14(2): 62 doi: 10.1111/1751-2980.12012
|
63 |
|
64 |
Paula Ministro, Diana Martins. Fecal biomarkers in inflammatory bowel disease: how, when and why?. Expert Review of Gastroenterology & Hepatology 2017; 11(4): 317 doi: 10.1080/17474124.2017.1292128
|
65 |
|
66 |
Kenta Kaneda, Fumio Saitoh, Hirom Shibusawa, Hidetaka Maegawa, Abbi R. Saniabadi, Nobuhito Kashiwagi, Akihiro Matsukawa. Correlation of neutrophil and monocyte derived interleukin-1 receptor antagonist and interleukin-8 with colitis severity in the rabbit. Cytokine 2011; 56(2): 508 doi: 10.1016/j.cyto.2011.07.008
|
67 |
Sukhminderjit Kaur, Chetana Vaishnavi, Prashant Kapoor, Ibrahim Masoodi. Retrospective assessment of fecal myeloperoxidase activity inClostridium difficileassociated diarrhea. Journal of Gastrointestinal Infections 2013; 3(1): 28 doi: 10.5005/jogi-3-1-28
|
68 |
David T Rubin, Stephen B Hanauer, Gary R Lichtenstein, Dermot P B McGovern, Miguel D Regueiro, Scott Snapper, Stephan Targan. Refining Treatment Paradigms in Inflammatory Bowel Disease: Assessing the Options for Individualized Therapy. The American Journal of Gastroenterology Supplements 2016; 3(3): 4 doi: 10.1038/ajgsup.2016.15
|
69 |
Sarah Fischer, Markus F. Neurath. Precision Medicine in Inflammatory Bowel Diseases. Clinical Pharmacology & Therapeutics 2017; 102(4): 623 doi: 10.1002/cpt.793
|
70 |
David B. Sachar. Role of Biomarkers in the Study and Management of Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2014; 20(12): 2511 doi: 10.1097/MIB.0000000000000135
|
71 |
Margalida Calafat, Eduard Cabré, Míriam Mañosa, Triana Lobatón, Laura Marín, Eugeni Domènech. High Within-day Variability of Fecal Calprotectin Levels in Patients with Active Ulcerative Colitis. Inflammatory Bowel Diseases 2015; 21(5): 1072 doi: 10.1097/MIB.0000000000000349
|
72 |
Alain M. Schoepfer, Christoph Beglinger, Alex Straumann, Michael Trummler, Pietro Renzulli, Frank Seibold. Ulcerative colitis. Inflammatory Bowel Diseases 2009; 15(12): 1851 doi: 10.1002/ibd.20986
|
73 |
Benjamin F Arnold, Clair Null, Stephen P Luby, Leanne Unicomb, Christine P Stewart, Kathryn G Dewey, Tahmeed Ahmed, Sania Ashraf, Garret Christensen, Thomas Clasen, Holly N Dentz, Lia C H Fernald, Rashidul Haque, Alan E Hubbard, Patricia Kariger, Elli Leontsini, Audrie Lin, Sammy M Njenga, Amy J Pickering, Pavani K Ram, Fahmida Tofail, Peter J Winch, John M Colford. Cluster-randomised controlled trials of individual and combined water, sanitation, hygiene and nutritional interventions in rural Bangladesh and Kenya: the WASH Benefits study design and rationale. BMJ Open 2013; 3(8): e003476 doi: 10.1136/bmjopen-2013-003476
|
74 |
Gang Guo, Wen Shi, Feiyu Shi, Wenqing Gong, Fanni Li, Guangju Zhou, Junjun She. Anti‐inflammatory effects of eriocitrin against the dextran sulfate sodium–induced experimental colitis in murine model. Journal of Biochemical and Molecular Toxicology 2019; 33(11) doi: 10.1002/jbt.22400
|
75 |
Gerhard Rogler, Xavier Aldeguer, Wolfgang Kruis, Anders Lasson, Ulrich Mittmann, Ken Nally, Laurent Peyrin-Biroulet, Alain Schoepfer, Morten Vatn, Stephan Vavricka, Robert Logan. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: Expert clinical opinion. Journal of Crohn's and Colitis 2013; 7(8): 670 doi: 10.1016/j.crohns.2013.02.014
|
76 |
D. T. Førland, E. Johnson, L. Sætre, T. Lyberg, I. Lygren, G. Hetland. Effect of an Extract Based on the Medicinal Mushroom Agaricus blazei Murill on Expression of Cytokines and Calprotectin in Patients with Ulcerative Colitis and Crohn’s disease. Scandinavian Journal of Immunology 2011; 73(1): 66 doi: 10.1111/j.1365-3083.2010.02477.x
|
77 |
Shno Asad, Christine Wegler, David Ahl, Christel A.S. Bergström, Mia Phillipson, Per Artursson, Alexandra Teleki. Proteomics-Informed Identification of Luminal Targets For In Situ Diagnosis of Inflammatory Bowel Disease. Journal of Pharmaceutical Sciences 2021; 110(1): 239 doi: 10.1016/j.xphs.2020.11.001
|
78 |
Taina Sipponen, Clas-Göran AF Björkesten, Martti Färkkilä, Hannu Nuutinen, Erkki Savilahti, Kaija-Leena Kolho. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology 2010; 45(3): 325 doi: 10.3109/00365520903483650
|
79 |
Filippo Vernia, Angelo Viscido, Mirko Di Ruscio, Gianpiero Stefanelli, Marco Valvano, Giovanni Latella. Fecal Lactoferrin and Other Putative Fecal Biomarkers in Crohn’s Disease: Do They Still Have a Potential Clinical Role?. Digestion 2021; 102(6): 833 doi: 10.1159/000518419
|
80 |
Roberta Caccaro, Renata D’Incá, Giacomo Carlo Sturniolo. Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease. Expert Review of Clinical Immunology 2010; 6(4): 551 doi: 10.1586/eci.10.26
|
81 |
Nathan Hargreaves Noguera, Dyana Carla Lima. Natural Plant Products in Inflammatory Bowel Diseases. 2023; : 173 doi: 10.1016/B978-0-323-99111-7.00003-9
|
82 |
Jeremy Meyer, Jacques Schrenzel, Alexandre Balaphas, Vaihere Delaune, Mohamed Abbas, Philippe Morel, Giaccomo Puppa, Laura Rubbia-Brandt, Philippe Bichard, Jean-Louis Frossard, Christian Toso, Nicolas C. Buchs, Frédéric Ris. Mapping of etiologies of computed tomography-proven acute colitis: a prospective cohort study. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-13868-w
|
83 |
Yilin Qian, Lei Ma, Mingyong Zeng, Zunying Liu. Amelioration of dextran sulfate sodium-induced colitis by autoinducer-2-deficient Lactiplantibacillus plantarum is mediated by anti-inflammatory effects and alleviation of dysbiosis of the gut microbiota. Frontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.1013586
|
84 |
Bincy P. Abraham, Sunanda Kane. Fecal Markers: Calprotectin and Lactoferrin. Gastroenterology Clinics of North America 2012; 41(2): 483 doi: 10.1016/j.gtc.2012.01.007
|
85 |
Duk Hwan Kim, Yehyun Park, Bun Kim, Seung Won Kim, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim, Jae Hee Cheon. Fecal calprotectin as a non‐invasive biomarker for intestinal involvement of Behçet's disease. Journal of Gastroenterology and Hepatology 2017; 32(3): 595 doi: 10.1111/jgh.13530
|
86 |
Maria Cappello, Gaetano Cristian Morreale. The Role of Laboratory Tests in Crohn's Disease. Clinical Medicine Insights: Gastroenterology 2016; 9: CGast.S38203 doi: 10.4137/CGast.S38203
|
87 |
Özgür Dandin, Mehmet Levhi Akin, Ahmet Ziya Balta, Ergün Yücel, Dursun Özgür Karakaş, Sezai Demirbaş, Sevim Özdemir, Apdullah Haholu. The Efficacy of Probiotic (Lactobacillus rhamnosus GG) and 5-ASA (Aminosalicylic Acid) in the Treatment of Experimental Radiation Proctitis in Rats. Indian Journal of Surgery 2015; 77(S2): 563 doi: 10.1007/s12262-013-0923-3
|
88 |
Ennio Lubrano, Michele Maria Luchetti, Devis Benfaremo, Daniele Mauro, Francesco Ciccia, Fabio Massimo Perrotta. Inflammatory bowel disease manifestations in spondyloarthritis: considerations for the clinician. Expert Review of Clinical Immunology 2021; 17(11): 1199 doi: 10.1080/1744666X.2021.1991315
|
89 |
Neil Anderson, Ibnauf Suliman, Tatiana Bandaletova, Austin Obichere, Rupert Lywood, Alexandre Loktionov. Protein biomarkers in exfoliated cells collected from the human rectal mucosa: implications for colorectal disease detection and monitoring. International Journal of Colorectal Disease 2011; 26(10): 1287 doi: 10.1007/s00384-011-1263-z
|
90 |
Kang-Moon Lee. Fecal Biomarkers in Inflammatory Bowel Disease. Intestinal Research 2013; 11(2): 73 doi: 10.5217/ir.2013.11.2.73
|
91 |
Gary R Lichtenstein, Dermot P B McGovern. Using Markers in IBD to Predict Disease and Treatment Outcomes: Rationale and a Review of Current Status. The American Journal of Gastroenterology Supplements 2016; 3(3): 17 doi: 10.1038/ajgsup.2016.17
|
92 |
Kristen A. Clarkson, Chad K. Porter, Kawsar R. Talaat, Robert W. Frenck, Cristina Alaimo, Patricia Martin, A. Louis Bourgeois, Robert W. Kaminski, David W. Pascual.
Shigella
-Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either Shigella flexneri 2a or Shigella sonnei
. mSphere 2021; 6(4) doi: 10.1128/mSphere.00122-21
|
93 |
Thomas A Judd, Andrew S Day, Daniel A Lemberg, Dan Turner, Steven T Leach. Update of fecal markers of inflammation in inflammatory bowel disease. Journal of Gastroenterology and Hepatology 2011; 26(10): 1493 doi: 10.1111/j.1440-1746.2011.06846.x
|
94 |
Anders Lasson, Per-Ove Stotzer, Lena Öhman, Stefan Isaksson, Maria Sapnara, Hans Strid. The intra-individual variability of faecal calprotectin: A prospective study in patients with active ulcerative colitis. Journal of Crohn's and Colitis 2014; doi: 10.1016/j.crohns.2014.06.002
|
95 |
Nada Abedin, Teresa Seemann, Sandra Kleinfeld, Jessica Ruehrup, Stefani Röseler, Christian Trautwein, Konrad Streetz, Gernot Sellge. Fecal Eosinophil Cationic Protein Is a Diagnostic and Predictive Biomarker in Young Adults with Inflammatory Bowel Disease. Journal of Clinical Medicine 2019; 8(12): 2025 doi: 10.3390/jcm8122025
|
96 |
K Takahashi, H Imaeda, T Fujimoto, H Ban, S Bamba, T Tsujikawa, M Sasaki, Y Fujiyama, A Andoh. Regulation of eotaxin-3/CC chemokine ligand 26 expression by T helper type 2 cytokines in human colonic myofibroblasts. Clinical and Experimental Immunology 2013; 173(2): 323 doi: 10.1111/cei.12117
|
97 |
Lei Min Yu, Ke Jia Zhao, Shuang Shuang Wang, Xi Wang, Bin Lu. Corticotropin‐releasing factor induces inflammatory cytokines via the NLRP6‐inflammatory cytokine axis in a murine model of irritable bowel syndrome. Journal of Digestive Diseases 2019; 20(3): 143 doi: 10.1111/1751-2980.12704
|
98 |
Milan Jovanovic, Nevena Gajovic, Natasa Zdravkovic, Marina Jovanovic, Milena Jurisevic, Danilo Vojvodic, Veljko Maric, Aleksandar Arsenijevic, Ivan Jovanovic. Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma. Mediators of Inflammation 2018; 2018: 1 doi: 10.1155/2018/8031328
|
99 |
Harland S. Winter, Piotr Krzeski, Melvin B. Heyman, Eduardo Ibarguen‐Secchia, Barbara Iwanczak, Maciej Kaczmarski, Jaroslaw Kierkus, Sanja Kolaček, Bankole Osuntokun, J. Antonio Quiros, Manoj Shah, Bruce Yacyshyn, Preston M. Dunnmon. High‐ and Low‐Dose Oral Delayed‐Release Mesalamine in Children With Mild‐to‐Moderately Active Ulcerative Colitis. Journal of Pediatric Gastroenterology and Nutrition 2014; 59(6): 767 doi: 10.1097/MPG.0000000000000530
|
100 |
James D. Lewis. The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease. Gastroenterology 2011; 140(6): 1817 doi: 10.1053/j.gastro.2010.11.058
|
101 |
Gulfam Ahmad, Belal Chami, Yuyang Liu, Angie L. Schroder, Patrick T. San Gabriel, Antony Gao, Genevieve Fong, XiaoSuo Wang, Paul K. Witting. The Synthetic Myeloperoxidase Inhibitor AZD3241 Ameliorates Dextran Sodium Sulfate Stimulated Experimental Colitis. Frontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.556020
|
102 |
Joanne C. Masterson, Eóin N. McNamee, Paul Jedlicka, Sophie Fillon, Joseph Ruybal, Lindsay Hosford, Jesús Rivera-Nieves, James J. Lee, Glenn T. Furuta. CCR3 Blockade Attenuates Eosinophilic Ileitis and Associated Remodeling. The American Journal of Pathology 2011; 179(5): 2302 doi: 10.1016/j.ajpath.2011.07.039
|
103 |
Emanuel Burri, Christoph Beglinger, Stefanie von Felten, Frank Serge Lehmann. Fecal Calprotectin and the Clinical Activity Index Are Both Useful to Monitor Medical Treatment in Patients with Ulcerative Colitis. Digestive Diseases and Sciences 2015; 60(2): 485 doi: 10.1007/s10620-014-3383-0
|
104 |
Cansel Turkay, Benan Kasapoglu. Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update. Clinics 2010; 65(2): 221 doi: 10.1590/S1807-59322010000200015
|
105 |
N S Ding, J A K McDonald, A Perdones-Montero, Douglas N Rees, S O Adegbola, R Misra, P Hendy, L Penez, J R Marchesi, E Holmes, M H Sarafian, A L Hart. Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn’s Disease. Journal of Crohn's and Colitis 2020; 14(8): 1090 doi: 10.1093/ecco-jcc/jjaa039
|